Intracranial stenting for nilotinib treatment-associated cerebrovascular stenosis in chronic myeloid leukemia.
Interv Neuroradiol
; 23(5): 527-530, 2017 Oct.
Article
en En
| MEDLINE
| ID: mdl-28583043
ABSTRACT
One of the second-generation tyrosine kinase inhibitors (TKIs), nilotinib, is increasingly used for imatinib-resistant or intolerant chronic myeloid leukemia (CML). Nilotinib is considered well tolerated with few side effects including hyperglycemia, hyperbilirubinemia and elevated levels of pancreatic enzymes. However, there is growing evidence that nilotinib accelerates atherosclerosis and causes peripheral arterial occlusive disease such as stroke, transient ischemic attack (TIA) and cardiovascular diseases. Herein, we report a case of a 74-year-old male CML patient with intracranial stenosis of the internal carotid artery developed during treatment with nilotinib successfully cured by the intracranial stent, Wingspan.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Pirimidinas
/
Proteínas Tirosina Quinasas
/
Leucemia Mielógena Crónica BCR-ABL Positiva
/
Arteria Carótida Interna
/
Stents
/
Estenosis Carotídea
Tipo de estudio:
Risk_factors_studies
Límite:
Aged
/
Humans
/
Male
Idioma:
En
Año:
2017
Tipo del documento:
Article